Clinical trials
Active, not recruiting Diabetic Retinopathy trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 25 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Oregon Health and Science University | 2 |
| University of Athens | 2 |
| 4D Molecular Therapeutics | 1 |
| AbbVie | 1 |
| Adverum Biotechnologies, Inc. | 1 |
| Alimera Sciences | 1 |
| Association for Innovation and Biomedical Research on Light and Image | 1 |
| Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health | 1 |
| Charles Drew University of Medicine and Science | 1 |
| Chinese University of Hong Kong | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetic Retinopathy | 25 |
| Diabetes Mellitus | 7 |
| Retinal Diseases | 4 |
| Diabetes Mellitus, Type 1 | 3 |
| Glaucoma | 3 |
| Blindness | 2 |
| Cataract | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Diabetic Nephropathies | 2 |
| Eye Diseases | 2 |
Trials
Showing 76 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.